49P Patient-reported Outcomes (pros) in Patients with Advanced Non-Small Cell Lung Cancer (ansclc) with Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Vs Chemotherapy (CHEMO): EMPOWER-Lung 1 Liver Metastases Subpopulation
JOURNAL OF THORACIC ONCOLOGY（2023）
关键词
Cancer Survivorship
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要